COMMUNIQUÉS West-GlobeNewswire

BioSenic S.A. : Information on the total number of voting rights and shares
30/04/2024
PRESS RELEASE – REGULATED INFORMATION Mont-Saint-Guibert, Belgium, April 30, 2024, 7.00 am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and [...]
BioSenic S.A. : Information relative au nombre total de droits de vote et d’actions
30/04/2024
COMMUNIQUE DE PRESSE – INFORMATION REGLEMENTEE Mont-Saint-Guibert, Belgique, le 30 avril 2024 à 07h00 CEST – BIOSENIC (Euronext Bruxelles et Paris : BIOS), la société en phase clinique spécialisée dans les maladies auto [...]
Combined General Meeting of May 22, 2024 - Availability of preparatory documents
30/04/2024
Press Release Paris – April 30, 2024 – EUROAPI’s shareholders are invited to attend the Combined General Meeting to be held on Wednesday May 22, 2024 at 10:00 a.m. (CET) at the Centre de Conférences Verso, 52 rue de la [...]
Assemblée Générale mixte du 22 mai 2024 - Modalités de mise à disposition ou de consultation des documents préparatoires
30/04/2024
Communiqué de presse Paris – Le 30 avril 2024 – Les actionnaires d’EUROAPI sont invités à participer à l’Assemblée Générale mixte qui se tiendra le mercredi 22 mai 2024 à 10h00 au Centre de Conférences Verso, 52 rue de [...]
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars
30/04/2024
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars Agreement clears path for launch of [...]
Stride Autism Centers Hosts Open House in Downers Grove, IL
30/04/2024
DOWNERS GROVE, Ill., April 29, 2024 (GLOBE NEWSWIRE) -- Stride Autism Centers (“Stride”) is thrilled to announce the grand opening of its newest center in Downers Grove, IL. Committed to becoming an integral part of the [...]
Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024
30/04/2024
FDA Provides Clarity on Path to Licensure for Remestemcel-L in SR-aGVHD and Rexlemestrocel-L in End-Stage Heart Failure NEW YORK, April 29, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global [...]
Hydreight Achieves Record Revenue, Files Audited Financial Statements for Fiscal Year 2023
30/04/2024
2023 Adjusted Revenue 1 record revenue of $17.05 million, an increase of 102% compared to 2022. 2023 GAAP revenue was $11.51 million an increase of 170% compared to 2022. 2023 gross margin of 43.11% compared to 43.00% [...]
Aurora Spine Corporation Announces Fourth Quarter and Fiscal 2023 Financial Results
30/04/2024
NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICES CARLSBAD, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a [...]
Mustang Bio Announces Pricing of $4 Million Public Offering
30/04/2024
WORCESTER, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell [...]
TFF Pharmaceuticals Announces Pricing of $4.8 Million Public Offering
30/04/2024
FORT WORTH, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (Nasdaq: TFFP) (the “Company” or “TFF Pharmaceuticals”), a clinical-stage biopharmaceutical company focused on developing and [...]
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
30/04/2024
Company Announcement Full approval based on global Phase 3 study demonstrating overall survival benefit of TIVDAK compared to chemotherapy TIVDAK is the first antibody-drug conjugate in this patient population to have [...]
Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology
30/04/2024
- Publication highlights administration of setmelanotide therapy resulted in a mean percent reduction in BMI of 15% at 16 weeks and 26% at one year of treatment - - Topline data from ongoing pivotal Phase 3 clinical [...]
BeyondSpring Files 2023 Annual Report on Form 20-F
29/04/2024
FLORHAM PARK, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer [...]
BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results
29/04/2024
- BeyondSpring Dosed First Patient of Two Phase 2 Investigator-Initiated Trials (IIT) in Plinabulin and Keytruda Combination Studies - SITC 2023 Presentation of the Phase 1 Topline Clinical and Mechanism Data of [...]
Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™
29/04/2024
ALACHUA, Fla. and TAMPA, Fla., April 29, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announces the first [...]
Cellectis publie ses résultats financiers du quatrième trimestre 2023 et de l’exercice 2023
29/04/2024
• Présentation de données préliminaires de l’essai clinique NATHALI-01 et de résultats cliniques actualisés de l’essai BALLI-01 lors de la réunion annuelle de l’American Society of Hematology (ASH) • Signature d’un [...]
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023
29/04/2024
• Preliminary results of NATHALI-01 and updated results of BALLI-01 Phase I clinical studies presented at the American Society of Hematology (ASH) 65th Annual Meeting • Execution of strategic collaboration and [...]
Travere Therapeutics to Report First Quarter 2024 Financial Results
29/04/2024
SAN DIEGO, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report first quarter 2024 financial results on Monday, May 6, 2024, after the close of the U.S. [...]

Pages